Specific inhibitors of puromycin-sensitive aminopeptidase with a 3-(halogenated phenyl)-2,4(1H,3H)-quinazolinedione skeleton

Article abstract of DOI:10.3987/COM-12-S(N)109

Specific puromycin-sensitive aminopeptidase (PSA) inhibitors with a 3-(halogenated phenyl)-2,4(1H,3H)-quinazolinedione skeleton were prepared and their structure-activity relationships were investigated. The nature (F, Cl or Br), number and position(s) of the halogen atom(s) introduced into the 3-phenyl group were concluded to be critical determinants of the inhibitory activity.

Full text of DOI:10.3987/COM-12-S(N)109

HETEROCYCLES, Vol. 86, No. 2, 2012
1449
HETEROCYCLES, Vol. 86, No. 2, 2012, pp. 1449 - 1463. © 2012 The Japan Institute of Heterocyclic Chemistry
Received, 20th August, 2012, Accepted, 26th September, 2012, Published online, 15th October, 2012
DOI: 10.3987/COM-12-S(N)109
SPECIFIC
INHIBITORS
OF
PUROMYCIN-SENSITIVE
AMINOPEPTIDASE WITH A 3-(HALOGENATED PHENYL)-2,4(1H,3H)-
QUINAZOLINEDIONE SKELETON
Yotaro Matsumoto,* Tomomi Noguchi-Yachide, Masaharu Nakamura,
Yusuke Mita, Akiyoshi Numadate, and Yuichi Hashimoto*
Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1
Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan
E-mail: matsumoto@iam.u-tokyo.ac.jp
Abstract – Specific puromycin-sensitive aminopeptidase (PSA) inhibitors with a
3-(halogenated phenyl)-2,4(1H,3H)-quinazolinedione skeleton were prepared and
their structure–activity relationships were investigated. The nature (F, Cl or Br),
number and position(s) of the halogen atom(s) introduced into the 3-phenyl group
were concluded to be critical determinants of the inhibitory activity.
INTRODUCTION
Puromycin-sensitive aminopeptidase (PSA: EC 3.4.11.14) is a ubiquitous, 100-kDa, Zn2+
metallopeptidase with a substrate specificity similar to that of aminopeptidase N (APN), and is present at
high concentrations in the brain (especially striatum, hippocampus and cerebellum).1-7 Although PSA was
initially purified as a candidate enkephalinase by Hersh and McKelvy in 1981,8,9 its localization
(predominantly in the cytoplasm) and its broad distribution in tissues argue against such a function.6,10-12
Instead, PSA has been implicated in many physiological processes, including regulation of the cell cycle
and onset of apoptosis,6,13 antigen processing in the class I MHC pathway,14-16 reproductive function,17,18
and regulation of neuropeptide levels.19,20
PSA was recently identified as a major peptidase digesting neuronal TAU protein and showing protective
activity against TAU-induced neurodegeneration in Alzheimer’s disease and other tauopathies.21-26 It was
also demonstrated that PSA is a major peptidase responsible for the degradation of polyglutamine repeats,
implicating this enzyme in the pathogenesis of polyQ diseases, including Huntington’s disease.27 PSA is
also involved in digestion of polyglutamine sequences released by proteasomes and removal of
neurotoxic polyglutamine-expanded Htt exon-1, ataxin-3, mutant synuclein and superoxide dismutase 1
via the autophagy system.28 These reports suggest that PSA might represent a novel degradation
Dedicated to Professor Ei-ichi Negishi (Purdue University) on the occasion of his 77th birthday

1450
HETEROCYCLES, Vol. 86, No. 2, 2012
mechanism targeting aggregate-prone neurotoxic protein substrates, including mutated Htt. Nevertheless,
the physiological role(s)/function(s) of PSA have remained unclear because of the low substrate
specificity of the enzyme and the lack of specific inhibitors.5-7,12
Puromycin (1) is an inhibitor of PSA that is effective at a low concentration,8 but it is not a specific
inhibitor of PSA. This is because the amino acid sequences recognized by 1, i.e., the catalytic site for
hydrolysis and the substrate-binding site, are similar among various neutral alanine-aminopeptidases.29
On the other hand, we have reported potent non-peptide, small-molecular PSA-specific inhibitors with a
homo-phthalimide or a quinazolinedione skeleton derived from thalidomide (2), including
N-(2,6-diethylphenyl)homophthalimide (PIQ-22, 3), 3-(2,6-diethylphenyl)-2,4(1H,3H)-quinazolinedione
(PAQ-22, 4) and 1-methyl-3-(2,6-diethylphenyl)-2,4(1H,3H)-quinazolinedione (MPAQ-22, 5), ANTAQ
(6) and DAMPAQ-22 (7) (Figure 1).28,30-40 They are all potent PSA-specific non-competitive inhibitors
with IC50 values of 3–8 M. The potencies of these inhibitors are comparable to those of bestatin and
actinonin (competitive inhibitors).30-39 By employing these PSA inhibitors, we identified possible roles of
the enzyme in cell mobility/invasion/apoptosis.32-34,37,41 These inhibitors also showed dose-dependent cell
invasion-inhibitory activity in a Matrigel assay using mouse melanoma B16F10/L5 cells, together with
low cell toxicity.38
On the other hand, a derivative of quinazolinedione named mdivi-1 (mitochondrial division inhibitor-1,
vide infra, Scheme 2) has been reported as a selective inhibitor of mitochondrial fission-related Drp1
(dynamin-related protein 1).42-44 Mdivi-1 inhibits GTPase activity by blocking the self-assembly of Drp1

HETEROCYCLES, Vol. 86, No. 2, 2012
1451
in vitro and causes rapid, reversible and dose-dependent formation of netlike mitochondria in wild-type
cells; this may be significant, because mitochondrial dysfunction is known to be a key event in the
pathogenesis of Huntington’s disease, and mutant huntingtin has been reported to increase GTPase
activity and to trigger mitochondrial fragmentation,45 suggesting possible nerve cell-protecting activity
of mdivi-1 in Huntington’s disease. Therefore, both PSA and Drp1 might play a role in the
pathophysiology of Huntington’s disease. In addition, mdivi-1 possesses a quite similar structure to
3-phenyl chlorinated derivatives of the above-mentioned quinazolinediones, including PAQ-22 (4). This
prompted us to examine the PSA-inhibitory activity of mdivi-1 and halogenated derivatives of
quinazolinedione.
In this article, we describe studies on the structure-activity relationship of 3-(fluorophenyl, chlorophenyl,
bromophenyl or silicon-substituted phenyl)-2,4(1H,3H)-quinazolinedione, as well as an examination of
the PSA-inhibitory activity of mdivi-1, with the aim of structural optimization of PSA inhibitors to
achieve potent and specific inhibitory activity.
RESULTS AND DISCUSSION
We first introduced a halogen atom(s) into the 3-phenyl group of 3-phenyl-2,4(1H,3H)-quinazolinedione
to obtain 11a-u. Also, 5-, 6-, 7- and 8-chloro-3-phenyl-2,4(1H,3H)-quinazolinediones (11v-y) were
prepared. The synthetic method is summarized in Scheme 1.38,46 Compounds 11a-y were prepared by
condensation of halophenyl isocyanate or phenyl isocyanate (9) with methyl anthranilate to give urea (10),
followed by cyclization of the resulting urea under basic conditions in one pot (Scheme 1).46 Halophenyl
isocyanate (9) was prepared from the corresponding haloaniline (8), triphosgene and triethylamine in
toluene. 3-((Trimethylsilyl)phenyl)quinazoline-2,4(1H,3H)-dione (12a-c) was prepared by condensation
and cyclization of methyl 2-isocyanatobenzoate and the corresponding trimethylsilylaniline (8) (Scheme
1).
O
X
Scheme 1. Reagents and
conditions: (a) triphosgene,
triethylamine, toluene, reflux,
2 h. (b) methyl anthranilate,
toluene, reflux 2 h. (c) 2 M
NaOH, EtOH, 80 °C, 30 min,
then acidified with 2 M HCl. (d)
methyl 2-isocyanatobenzoate,
triethylamine, MeCN, 80 °C, 4 h.
N
d
Y
X
N
O
H2N
H
11a u
- : X = halogen, Y = H
11v-y: X = H, Y = Cl
8
12a-c
: X = TMS, Y = H
a
c
O
OMe
NH
Y
b
X
X
OCN
O
N
H
9
10

1452
HETEROCYCLES, Vol. 86, No. 2, 2012
Inhibition of PSA by these compounds was assessed by measuring 7-amino-4-methylcoumarin (AMC)
liberated from L-methylcoumarylamide (Ala-AMC) using intact human acute lymphoblastic leukemia
MOLT-4 cells.33,36,37,47 In order to examine the specificity of PSA-inhibitory activity, inhibition of another
aminopeptidase, APN, by the compounds was also assessed by measuring AMC liberated from Ala-AMC
with human promyelocytic leukemia HL-60 cells. All experiments were performed at least in duplicate,
and the IC50 values obtained are given in Tables 1 and 2.
As shown in Table 1, all of the fluoro-substituted compounds (11a—11g) were inactive (the IC50 values
are higher than 100 M, though slight PSA inhibition was observed at this concentration; data not shown).
Concerning chloro derivatives 11h—11n, all of the compounds, except the para- (11j) and
3,5-disubstituted (11l) compounds, showed moderate PSA-inhibitory activity with IC50 values of
2.4—67.1 Among the active chlorinated derivatives, the activity decreased in the order of

HETEROCYCLES, Vol. 86, No. 2, 2012
1453
2,3,4,5,6-pentasubstituted (11n) > 2,4,6-trisubstituted (11m) > 2,6-disubstituted (11k) > meta-substituted
(11i) > ortho-substituted (11h). This tendency is just the same as for the brominated derivatives
11o—11u, and the para-bromo (11q) and 3,5-dibromo (11s) compounds are inactive, as in the case of the
corresponding chlorinated derivatives, 11j and 11l, respectively. Like PAQ-22 (4), none of the
compounds listed in Table 1 showed apparent APN-inhibitory activity.38 Pentahalogenated derivatives,
11n and 11u, are more potent PSA-selective inhibitors than PAQ-22 (4). Among the active bromo and
chloro derivatives, the bromo derivative is a more potent PSA inhibitor than the corresponding chloro
derivative, i.e., 11o >11h, 11p >11i, 11r >11k, 11t >11m, and 11u >11n. It seems quite difficult to
interpret these structure-activity relationships at this stage. Among the mono-substituted derivatives,
11h—11j and 11o—11q, meta-substitution seems to be best for PSA-inhibitory activity, while
ortho-substitution seems moderately effective, and para-substitution seems ineffective. However, among
disubstituted derivatives, i.e., 11k, 11l, 11o and 11q, the meta-substituted (3,5-disubstitution) compounds
are inactive, whereas para-substitution (2,6-disubstitution) seems to be effective.
As for the effects of a substituent on the aromatic ring of the quinazolinedione moiety (11v—11y), only
11y showed slight PSA-inhibitory activity (Table 2). This result is consistent with our previously reported
structural development studies of PAQ-22 (4), in which we established the importance of the 8-position
on the aromatic ring of the quinazolinedione moiety for PSA-inhibitory activity.38
Next, 3-(trimethylsilyl-substituted phenyl)-2,4(1H,3H)-quinazolinediones 12a—12c were investigated to
check the influence of the steric factor on PSA-inhibitory activity (Table 2). Among compounds
12a—12c, only ortho-substituted derivative 12a showed relatively potent PSA-inhibitory activity, while
among the mono-halogenated derivatives, meta-substituted ones are more potent than the corresponding
ortho-derivatives.

1454
HETEROCYCLES, Vol. 86, No. 2, 2012
Finally, we investigated whether mitochondrial division inhibitor (mdivi)-1 inhibits PSA.
Mdivi-1 was prepared as shown in Scheme 2, by treatment of the amide compound (15) with CS2 and
DBU in DMF. Amido compound (15) was prepared from 2-nitrobenzoyl chloride (13) and
2,4-dichloro-5-methoxyaniline (14). The aminopeptidase-inhibitory activities of mdivi-1 were evaluated.
These results are summarized in terms of IC50 values in Scheme 2. Inhibitory activity of mdivi-1 towards
PSA was more potent than that of PAQ-22 (4), but mdivi-1 showed no inhibitory activity toward APN.
Therefore, even though mdivi-1 is a selective Drp1 inhibitor (vide infra), it should be noted that a part of
its biological activities may be elicited by inhibition of PSA.
Cl
Cl
Cl
Cl
Cl
Cl
O
O
1. H2, Pd/C
DMF, rt, 12 h
87%
COCl
NO2
H2N
OMe
N
OMe
N
OMe
14
H
2. CS2, DBU
DMF, reflux, 15 h
96%
pyridine, CH2Cl2
rt, 20 min, 87%
NO2
15
N
H
S
13
mdivi-1 (16)

PSA IC50 = 0.71
APN IC50 >100
M

M
Scheme 2
16
)
. Preparation and Aminopeptidase (PSA and APN)-Inhibitory Activity (IC50 values) of mdivi-1 (
In conclusion, specific inhibitors of PSA with 3-(halogenated phenyl)- and 3-(trimethylsilyl-substituted
phenyl)-2,4(1H,3H)-quinazolinedione structures were prepared and their structure–activity relationships
were investigated. Pentachlorinated (11n) and pentabrominated (11u) derivatives were discovered to be
potent PSA-specific inhibitors among the prepared compounds. Compounds 12a (a silicon-containing
derivative) and mdivi-1 were also rather potent PSA-selective inhibitors. These results indicate generality
of the quinazolinedione skeleton as a platform for specific inhibitors of PSA.
EXPERIMENTAL
Abbreviations. CS2,
carbon
disulfide;
DBU,
1,8-diazabicyclo[5.4.0]undec-7-ene;
DMF,
N,N-dimethylformamide; DMSO, dimethyl sulfoxide; EtOH, ethanol; EtOAc, ethyl acetate; Et3N,
triethylamine; Hex, n-hexane; MeOH, methanol.
General Comments. Melting points were determined with a Yanagimoto hot-stage melting point
apparatus and are uncorrected. Elemental analyses were carried out in the Microanalytical Laboratory,
Faculty of Pharmaceutical Sciences, University of Tokyo, and results were within ±0.3% of the
theoretical values. NMR spectra were recorded on a JEOL JNM- -500 (500 MHz) spectrometer. Unless
otherwise noted, samples were dissolved in CDCl3. Chemical shifts are expressed in  (ppm) values, and
coupling constants are expressed in hertz (Hz). NMR spectra were referenced to tetramethylsilane as an

HETEROCYCLES, Vol. 86, No. 2, 2012
1455
internal standard. The following abbreviations are used: s = singlet, d = doublet, t = triplet, quint = quintet,
m = multiplet, and brs = broad singlet. Mass spectra were recorded on a JEOL spectrometer.
Materials. Unless otherwise noted, materials were purchased from Tokyo Kasei Co., Aldrich Inc., and
other commercial suppliers and were used after appropriate purification (distillation or recrystallization).
General Procedure for the Synthesis of 3-Substituted 2,4(1H,3H)-Quinazolinediones from Amines
To a mixture of amine (8) (1.0 mmol) and Et3N (2.0 mmol) in toluene (10 mL) was added triphosgene
(0.40 mmol), and the resulting solution was heated at reflux until the starting amine disappeared (for ca. 2
h). Next, the appropriate methyl anthranilate (1.0 mmol) was added, and the resulting mixture was stirred
at reflux for 2 h. The solvent was removed under reduced pressure, and EtOH (2 mL) and 2 N NaOH
solution (1 mL) were added to the residue. The reaction mixture was stirred at 80 °C for 30 min. This
solution was cooled, diluted with water, acidified with 2 N HCl (ca. 2 mL), and extracted with EtOAc.
The organic layer was washed with water and brine, dried over MgSO4 and concentrated under reduced
pressure. Purification by silica gel column chromatography (eluent: EtOAc/hexane or CHCl3/MeOH)
gave the 3-substituted 2,4(1H,3H)-quinazolinedione (11a-y).
3-(2-Fluorophenyl)-2,4(1H,3H)-quinazolinedione (11a) According to the general procedure, 11a was
obtained in 70% yield as pale yellow solid after recrystallization from CHCl3; 1H-NMR (500 MHz, CDCl3)
δ: 8.36 (br s, 1H), 8.14 (d, 1H, J = 8.0 Hz), 7.65 (dd, 1H, J = 7.6, 7.9 Hz), 7.47 (m, 1H), 7.35-7.24 (m, 4H),
7.16 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 257 (M+H)+; Anal. Calcd for C14H9FN2O2: C, 65.62; H, 3.54; N,
10.93. Found: C, 65.62; H, 3.64; N, 10.90.
3-(3-Fluorophenyl)-2,4(1H,3H)-quinazolinedione (11b) According to the general procedure, 11b was
1
obtained in 67% yield as white solid after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3) δ:
8.41 (br s, 1H), 8.17 (d, 1H, J = 8.0 Hz), 7.66 (dd, 1H, J = 7.3, 8.0 Hz), 7.49 (m, 1H), 7.30-7.03 (m, 5H);
FAB-MS m/z: 257 (M+H)+.
3-(4-Fluorophenyl)-2,4(1H,3H)-quinazolinedione (11c) According to the general procedure, 11c was
obtained in 59% yield as white plates after recrystallization from CHCl3; 1H-NMR (500 MHz, CDCl3) δ:
8.36 (br s, 1H), 8.17 (d, 1H, J = 8.0 Hz), 7.66 (dd, 1H, J = 7.4, 7.9 Hz), 7.29-7.20 (m, 5H), 7.03 (d, 1H, J
= 8.6 Hz); FAB-MS m/z: 257 (M+H)+; Anal. Calcd for C14H9FN2O2: C, 65.62; H, 3.54; N, 10.93. Found:
C, 65.52; H, 3.68; N, 11.02.
3-(2,6-Difluorophenyl)-2,4(1H,3H)-quinazolinedione (11d) According to the general procedure, 11d

1456
HETEROCYCLES, Vol. 86, No. 2, 2012
1
was obtained in 44% yield as pale yellow solid after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.35 (br s, 1H), 8.18 (d, 1H, J = 7.9 Hz), 7.67 (dd, 1H, J = 7.3, 7.9 Hz), 7.45 (m, 1H), 7.29 (dd,
1H, J = 7.3, 7.9 Hz), 7.10-7.05 (m, 3H); FAB-MS m/z: 275 (M+H)+; Anal. Calcd for C14H8F2N2O2: C,
61.32; H, 2.94; N, 10.22. Found: C, 61.12; H, 3.17; N, 10.06.
3-(3,5-Difluorophenyl)-2,4(1H,3H)-quinazolinedione (11e) According to the general procedure, 11e
1
was obtained in 43% yield as white crystals after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.45 (br s, 1H), 8.13 (d, 1H, J = 7.9 Hz), 7.66 (dd, 1H, J = 7.3, 8.5 Hz), 7.26 (dd, 1H, J = 7.3,
7.9 Hz), 7.16 (d, 1H, J = 8.5 Hz), 6.96-6.87 (m, 3H); FAB-MS m/z: 275 (M+H)+; Anal. Calcd for
C14H8F2N2O2: C, 61.32; H, 2.94; N, 10.22. Found: C, 61.15; H, 3.07; N, 10.17.
3-(2,4,6-Trifluorophenyl)-2,4(1H,3H)-quinazolinedione (11f) According to the general procedure, 11f
1
was obtained in 73% yield as yellow powder after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.18 (d, 1H, J = 8.0 Hz), 8.01 (br s, 1H), 7.69 (dd, 1H, J = 8.6, 7.4 Hz), 7.30 (dd, 1H, J = 8.0,
7.4 Hz), 7.06 (d 1H, J = 8.6 Hz), 6.86 (t, 2H, J = 7.9, 8.6 Hz); FAB-MS m/z: 293 (M+H)+; Anal. Calcd
for C14H7F3N2O2: C, 57.54; H, 2.41; N, 9.57. Found: C, 57.42; H, 2.64; N, 9.51.
3-(2,3,4,5,6-Pentafluorophenyl)-2,4(1H,3H)-quinazolinedione (11g) According to the general
procedure, 11g was obtained in 88% yield as colorless plates after recrystallization from CHCl3. mp
1
273-274 °C; H-NMR (500 MHz, CDCl3) δ: 9.43 (br s, 1H), 8.18 (d, 1H, J = 7.9 Hz), 7.70 (dd, 1H, J =
7.3, 7.9 Hz), 7.32 (dd, 1H, J = 7.3, 7.9 Hz), 7.10 (d, 1H, J = 8.5 Hz); FAB-MS m/z: 329 (M+H)+; Anal.
Calcd for C14H5F5N2O2: C, 51.23; H, 1.54; N, 8.54. Found: C, 51.17; H, 1.79; N, 8.54.
3-(2-Chlorophenyl)-2,4(1H,3H)-quinazolinedione (11h) According to the general procedure, 11h was
1
obtained in 51% yield as white powder after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3)
δ: 8.82 (br s, 1H), 8.18 (d, 1H, J = 8.0 Hz), 7.65 (dd, 1H, J = 7.3, 8.0 Hz), 7.60 (m, 1H), 7.45 (m, 2H),
7.37 (m, 1H), 7.28 (m, 1H, J = 8.0 Hz), 7.04 (d, 1H, J = 8.0 Hz); FAB-MS m/z: 273 (M+H)+; Anal. Calcd
for C14H9ClN2O2: C, 61.66; H, 3.33; N, 10.27. Found: C, 61.65; H, 3.58; N, 10.22.
3-(3-Chlorophenyl)-2,4(1H,3H)-quinazolinedione (11i) According to the general procedure, 11i was
1
obtained in 69% yield as pale yellow powder after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.32 (br s, 1H), 8.17 (d, 1H, J = 7.3 Hz), 7.66 (dd, 1H, J = 6.7, 8.5 Hz), 7.46 (m, 2H), 7.33 (s,
1H), 7.30-7.20 (m, 2H), 7.04 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 273 (M+H)+; Anal. Calcd for
C14H9ClN2O2·0.2H2O: C, 60.86; H, 3.43; N, 10.14. Found: C, 60.98; H, 3.39; N, 10.21.

HETEROCYCLES, Vol. 86, No. 2, 2012
1457
3-(4-Chlorophenyl)-2,4(1H,3H)-quinazolinedione (11j) According to the general procedure, 11j was
1
obtained in 74% yield as white crystals after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3)
δ: 8.17 (d, 1H, J = 7.3 Hz), 8.05 (br s, 1H), 7.66 (m, 1H), 7.50 (d, 2H, J = 8.6 Hz), 7.29-7.23 (m, 3H),
7.04 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 273 (M+H)+; Anal. Calcd for C14H9ClN2O2·0.2H2O: C, 60.86; H,
3.43; N, 10.14. Found: C, 61.12; H, 3.46; N, 10.15.
3-(2,6-Dichlorophenyl)-2,4(1H,3H)-quinazolinedione (11k) According to the general procedure, 11d
11k was obtained in 57% yield as white powder after recrystallization from CHCl3. mp >300 °C;
1H-NMR (500 MHz, CDCl3) δ: 8.82 (br s, 1H), 8.23 (d, 1H, J = 7.9 Hz), 7.68 (dd, 1H, J = 7.3, 8.5 Hz),
7.50 (d, 2H, J = 8.5 Hz), 7.38 (dd, 1H, J = 7.3, 8.5 Hz), 7.30 (dd, 1H, J = 7.3, 7.9 Hz), 7.07 (d, 1H, J = 8.5
Hz); FAB-MS m/z: 307 (M+H)+, 309 (M+H)+; Anal. Calcd for C14H8Cl2N2O2: C, 54.75; H, 2.63; N, 9.12.
Found: C, 54.70; H, 2.75; N, 9.00.
3-(3,5-Dichlorophenyl)-2,4(1H,3H)-quinazolinedione (11l) According to the general procedure, 11l was
1
obtained in 68% yield as white crystals after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3)
δ: 8.17 (br s, 1H), 8.16 (d, 1H, J = 7.4 Hz), 7.68 (dd, 1H, J = 8.0, 7.4 Hz), 7.47 (s, 1H), 7.30 (dd, 1H, J =
8.0, 7.4 Hz), 7.24 (s, 1H), 7.23 (s, 1H), 7.05 (d, 1H, J = 8.0 Hz); FAB-MS m/z: 307 (M+H)+, 309 (M+H)+;
Anal. Calcd for C14H8Cl2N2O2: C, 54.75; H, 2.63; N, 9.12. Found: C, 54.73; H, 2.72; N, 9.15.
3-(2,4,6-Trichlorophenyl)-2,4(1H,3H)-quinazolinedione (11m) According to the general procedure,
11m was obtained in 68% yield as colorless cubes after recrystallization from CHCl3; 1H-NMR (500 MHz,
CDCl3) δ: 8.65 (br s, 1H), 8.19 (d, 1H, J = 7.9 Hz), 7.69 (dd, 1H, J = 7.9 Hz), 7.52 (s, 2H), 7.31 (dd, 1H,
J = 7.9, 7.3 Hz), 7.07 (d 1H, J = 8.5 Hz); FAB-MS m/z: 341 (M+H)+, 343 (M+H)+; Anal. Calcd for
C14H7Cl3N2O2: C, 49.23; H, 2.07; N, 8.20. Found: C, 49.09; H, 2.20; N, 8.18.
3-(2,3,4,5,6-Pentachlorophenyl)-2,4(1H,3H)-quinazolinedione (11n) According to the general
1
procedure, 11n was obtained in 37% yield as white crystals after recrystallization from CHCl3; H-NMR
(500 MHz, CDCl3) δ: 8.84 (br s, 1H), 8.19 (d, 1H, J = 7.9 Hz), 7.71 (dd, 1H, J = 7.3, 7.9 Hz), 7.32 (dd,
1H, J = 7.3, 7.9 Hz), 7.09 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 409 (M+H)+, 411 (M+H)+, 413 (M+H)+;
Anal. Calcd for C14H5Cl5N2O2: C, 40.97; H, 1.23; N, 6.82. Found: C, 41.17; H, 1.39; N, 6.83.
3-(2-Bromophenyl)-2,4(1H,3H)-quinazolinedione (11o) According to the general procedure, 11o was
1
obtained in 94% yield as white needles after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3)
δ : 8.76 (br s, 1H), 8.18 (d, 1H, J = 8.0 Hz), 7.77 (d, 1H, J = 8.0 Hz), 7.65 (dd, 1H, J = 7.4, 7.9 Hz), 7.50

1458
HETEROCYCLES, Vol. 86, No. 2, 2012
(dd, 1H, J = 7.9, 8.0 Hz), 7.37 (m, 2H), 7.28 (m, 1H), 7.04 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 317
(M+H)+, 319 (M+H)+; Anal. Calcd for C14H9BrN2O2·1/3CHCl3: C, 48.27; H, 2.64; N, 7.86. Found: C,
48.20; H, 2.75; N, 7.79.
3-(3-Bromophenyl)-2,4(1H,3H)-quinazolinedione (11p) According to the general procedure, 11p was
obtained in 49% yield as colorless cubes after recrystallization from CHCl3; 1H-NMR (500 MHz, CDCl3)
δ: 8.86 (br s, 1H), 8.16 (d, 1H, J = 8.0 Hz), 7.66-7.60 (m, 2H), 7.49 (s, 1H), 7.41 (dd, 1H, J = 7.9, 8.6 Hz),
7.27 (m, 2H), 7.02 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 317 (M+H)+, 319 (M+H)+; Anal. Calcd for
C14H9BrN2O2: C, 53.02; H, 2.86; N, 8.83. Found: C, 52.97; H, 2.89; N, 8.87.
3-(4-Bromophenyl)-2,4(1H,3H)-quinazolinedione (11q) According to the general procedure, 11q was
1
obtained in 83% yield as pale yellow needles after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.18 (br s, 1H), 8.17 (d, 1H, J = 7.9 Hz), 7.66 (m, 1H), 7.65 (d, 1H, J = 8.6 Hz), 7.28 (m, 1H),
7.37 (m, 1H), 7.18 (d, 1H, J = 8.6 Hz), 7.03 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 317 (M+H)+, 319 (M+H)+;
Anal. Calcd for C14H9BrN2O2: C, 53.02; H, 2.86; N, 8.83. Found: C, 52.81; H, 2.88; N, 8.68.
3-(2,6-Dibromophenyl)-2,4(1H,3H)-quinazolinedione (11r) According to the general procedure, 11r
1
was obtained in 49% yield as white plates after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.21 (d, 1H, J = 7.9 Hz), 8.07 (br s, 1H), 7.71-7.67 (m, 3H), 7.32-7.21 (m, 2H), 7.07 (d, 1H, J
= 7.9 Hz); FAB-MS m/z: 395 (M+H)+, 397 (M+H)+, 399 (M+H)+; Anal. Calcd for C14H8Br2N2O2: C,
42.46; H, 2.04; N, 7.07. Found: C, 42.31; H, 2.21; N, 7.04.
3-(3,5-Dibromophenyl)-2,4(1H,3H)-quinazolinedione (11s) According to the general procedure, 11s
was obtained in 81% yield as white solid after recrystallization from CHCl3; 1H-NMR (500 MHz, CDCl3)
δ: 8.29 (br s, 1H), 8.16 (d, 1H, J = 7.9 Hz), 7.77 (s, 1H), 7.67 (dd, 1H, J = 7.3, 8.5 Hz), 7.43 (s, 2H), 7.29
(dd, 1H, J = 7.3, 7.9 Hz), 7.05 (d, 1H, J = 8.5 Hz); FAB-MS m/z: 395 (M+H)+, 397 (M+H)+, 399 (M+H)+;
Anal. Calcd for C14H8Br2N2O2·0.5H2O: C, 41.51; H, 2.24; N, 6.92. Found: C, 41.66; H, 2.18; N, 6.91.
3-(2,4,6-Tribromophenyl)-2,4(1H,3H)-quinazolinedione (11t) According to the general procedure, 11t
1
was obtained in 53% yield as white cubes after recrystallization from CHCl3; H-NMR (500 MHz,
CDCl3) δ: 8.80 (br s, 1H), 8.19 (d, 1H, J = 7.9 Hz), 7.87 (s, 2H), 7.68 (t, 1H, J = 7.3, 7.9 Hz), 7.30 (t, 1H,
J = 7.3, 7.9 Hz), 7.08 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 475 (M+H)+, 477 (M+H)+; Anal. Calcd for
C14H7Br3N2O2: C, 35.41; H, 1.49; N, 5.90. Found: C, 35.36; H, 1.58; N, 5.89.

HETEROCYCLES, Vol. 86, No. 2, 2012
1459
3-(2,3,4,5,6-Pentabromophenyl)-2,4(1H,3H)-quinazolinedione (11u) According to the general
procedure, 11u was obtained in 50% yield as white needles after recrystallization from CHCl3/MeOH.;
1H-NMR (500 MHz, CDCl3) δ: 8.97 (br s, 1H), 8.19 (d, 1H, J = 8.0 Hz), 7.70 (dd, 1H, J = 7.3, 8.5 Hz),
7.32 (dd, 1H, J = 7.3, 8.0 Hz), 7.09 (d, 1H, J = 8.5 Hz); FAB-MS m/z: 630 (M+H)+, 632 (M+H)+, 634
(M+H)+, 636 (M+H)+ ; Anal. Calcd for C14H5Br5N2O2·0.5MeOH: C, 26.84; H, 1.12; N, 4.32. Found: C,
26.84; H, 1.16; N, 4.34.
5-Chloro-3-phenyl-2,4(1H,3H)-quinazolinedione (11v) According to the general procedure, 11v was
1
obtained in 28% yield as white solid after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3) δ:
7.52 (br s, 1H), 7.42 (d, 2H, J = 7.3 Hz), 7.33-7.30 (m, 3H), 7.21 (t, 1H, J = 7.9 Hz), 7.06 (t, 1H, J = 7.3
Hz), 6.99 (d, 1H, J = 7.9 Hz); FAB-MS m/z: 273 (M+H)+.
6-Chloro-3-phenyl-2,4(1H,3H)-quinazolinedione (11w) According to the general procedure, 11w was
1
obtained in 73% yield as white powder after recrystallization from CHCl3; H-NMR (500 MHz, CDCl3)
δ: 8.62 (br s, 1H), 8.07 (s, 1H), 7.51-7.44 (m, 4H), 7.26 (m, 2H), 6.98 (d, 1H, J = 8.5 Hz); FAB-MS m/z:
273 (M+H)+; Anal. Calcd for C14H9ClN2O2·0.2H2O: C, 60.86; H, 3.43; N, 10.14. Found: C, 61.04; H,
3.52; N, 10.20.
7-Chloro-3-phenyl-2,4(1H,3H)-quinazolinedione (11x) According to the general procedure, 11x was
1
obtained in 36% yield as colorless crystalline needles after recrystallization from CHCl3; H-NMR (500
MHz, CDCl3) δ: 8.17 (br s, 1H), 8.10 (d, 1H, J = 8.5 Hz), 7.54 (t, 2H, J = 7.3, 7.9 Hz), 7.47 (m, 1H), 7.29
(d, 2H, J = 7.3 Hz), 7.23 (d, 1H, J = 8.5 Hz), 7.05 (s, 1H); FAB-MS m/z: 273 (M+H)+; Anal. Calcd for
C14H9ClN2O2: C, 61.66; H, 3.33; N, 10.27. Found: C, 61.49; H, 3.46; N, 10.19.
8-Chloro-3-phenyl-2,4(1H,3H)-quinazolinedione (11y) According to the general procedure, 11y was
1
obtained in 62% yield as colorless crystalline needles after recrystallization from CHCl3; H-NMR (500
MHz, CDCl3) δ: 8.73 (br s, 1H), 8.09 (d, 1H, J = 8.0 Hz), 7.67 (d, 1H, J = 7.9 Hz), 7.53-7.44 (m, 3H),
7.29 (d, 2H, J = 8.0 Hz), 7.19 (dd, 1H, J = 7.9, 8.0 Hz); FAB-MS m/z: 273 (M+H)+; Anal. Calcd for
C14H9ClN2O2: C, 61.66; H, 3.33; N, 10.27. Found: C, 61.63; H, 3.41; N, 10.22.
General procedure for TMS compounds 12a-12c
Trimethylsilylaniline was prepared according to the reported method.48 To a solution of
trimethylsilylaniline in acetonitrile were added methyl 2-isocyanatobenzoate (1.05 eq) and triethylamine
(1.0 eq) at rt, and the mixture was stirred at 80 °C for 4 h. The reaction mixture was evaporated. The

1460
HETEROCYCLES, Vol. 86, No. 2, 2012
residue was washed with hexane and, if necessary, recrystallized from CHCl3 to give 12a-12c (54.8
-91.2%).
3-(2-(Trimethylsilyl)phenyl)quinazoline-2,4(1H,3H)-dione (12a) According to the general procedure,
1
12a was obtained in 55% yield as white solid; mp 272-273 °C; H-NMR (500 MHz, CDCl3) δ: 9.23 (s,
1H), 8.16 (d, 1H, J = 7.9 Hz), 7.71 (d, 1H, J = 7.3 Hz), 7.61-7.47 (m, 3H), 7.26-7.23 (m, 1H), 7.18 (d, 1H,
13
J = 7.3 Hz), 6.97 (s, 1H), 0.16 (9H, s); C-NMR (500 MHz, CDCl3) : 163.47, 152.55, 140.42, 139.55,
139.23, 136.38, 135.77, 131.03, 129.51, 129.04, 128.91, 123.96, 115.87, 115.42, 0.00; HRMS (FAB):
calcd for C17H19N2O2Si 311.1216, found 311.1217 (M+H)+.
3-(3-(Trimethylsilyl)phenyl)quinazoline-2,4(1H,3H)-dione (12b) According to the general procedure,
12b was obtained in 90% yield as white solid; mp >300 °C; 1H-NMR (500 MHz, CDCl3) δ: 10.04 (s, 1H),
8.14 (d, 1H, J = 7.9 Hz), 7.64 (d, 1H, J = 7.3 Hz), 7.56-7.52 (m, 1H), 7.50-7.47 (m, 1H), 7.42 (s, 1H),
7.31-7.29 (m, 1H), 7.26-7.20 (m, 1H), 6.80 (d, 1H, J = 7.9 Hz), 0.28 (9H, s); 13C-NMR (500 MHz,
CDCl3) : 162.60, 151.78, 142.24, 138.77, 135.30, 134.35, 133.80, 133.13, 128.85, 128.80, 128.63,
123.43, 115.20, 114.86, 1.17; HRMS (FAB): calcd for C17H19N2O2Si 311.1216, found 311.1219 (M+H)+.
3-(4-(Trimethylsilyl)phenyl)quinazoline-2,4(1H,3H)-dione (12c) According to the general procedure,
1
12c was obtained in 91% yield as white solid; mp >300 °C; H-NMR (500 MHz, CDCl3) δ: 9.82 (s, 1H),
8.14 (d, 1H, J = 7.9 Hz), 7.69 (d, 2H, J = 7.3 Hz), 7.54-7.51 (m, 1H), 7.30 (d, 2H, J = 7.9 Hz), 7.26-7.20
(m, 1H), 6.92 (d, 1H, J = 7.9 Hz), 0.31 (9H, s).
N-(2,4-Dichloro-5-methoxyphenyl)-2-nitrobenzamide (15)
To a solution of 2,4-dichloro-5-methoxyaniline (14) (384 mg, 2.00 mmol) and pyridine (0.1 mL) in
CH2Cl2 (2 mL) was added 2-nitrobenzoyl chloride (13) (371 mg, 2.0 mmol). The mixture was stirred for
20 min at rt, and a pale yellow solid was precipitated. The precipitate was collected by filtration and
washed with AcOEt to afford 15 (595 mg, 87%) as pale yellow solid.
1H-NMR (500 MHz, CDCl3) δ: 8.28 (s, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.88 (brs, 1H), 7.78 (m, 1H), 7.69
(m, 2H), 7.42 (s, 1H), 3.98 (s, 3H).
3-(2,4-Dichloro-5-methoxyphenyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one (mdivi-1) (16)
341 mg (1.0 mmol) of 15 was dissolved in DMF (5 mL) and hydrogenated (1 bar H2) over 10 %
palladium on charcoal. The mixture was filtered through a pad of Celite. The filtrate was diluted with
AcOEt and washed with water and brine. The organic layer was dried over MgSO4 and concentrated to

HETEROCYCLES, Vol. 86, No. 2, 2012
1461
afford 2-amino-N-(2,4-dichloro-5-methoxyphenyl)benzamide (272 mg, 87%) as pale yellow solid.
1H-NMR (500 MHz, CDCl3) δ
m, 2H), 7.52 (d, 1H), 7.40 (s, 1H), 7.29 (m, 1H), 6.75 (m, 2H), 5.59
(brs, 2H), 3.96 (s, 3H).
To a solution of 2-amino-N-(2,4-dichloro-5-methoxyphenyl)benzamide (80.6 mg, 260 mmol) and CS2
(300 mL, 5.00 mmol) in DMF (2 mL) was added DBU (38.7 mL, 258 mmol). The mixture was stirred for
15.5 h at rt, then diluted with AcOEt. The organic layer was washed with 2 N HCl aq., water and brine,
dried over anhydrous magnesium sulfate and concentrated to afford 16 (87.7 mg, 96%). The product was
obtained as pale yellow solid from CHCl3/MeOH.
1H-NMR (500 MHz, CDCl3)  : 8.16 (d, 1H, J = 7.95 Hz), 7.72 (m, 1H), 7.58 (s, 1H), 7.35 (m, 1H), 7.24
(d, 1H, J = 8.55 Hz), 6.89 (s, 1H), 3.90 (s, 3H); MS (FAB) m/z 353, 355, 357 (M+H)+.
Cells MOLT-4 cells or HL-60 cells were maintained in RPMI1640 medium supplemented with 10%
v/v fetal bovine serum at 37 °C under an atmosphere of 5% CO2 in air.
Assay of Enzyme Activities PSA and APN activities were evaluated in the usual way, by measuring
7-amino-4-methylcoumarin (AMC) liberated from L-alanine 4-methylcoumaryl-7-amide (Ala-MCA).
Cell suspension: Cells were collected by centrifugation (2000 rpm, 5 min, 4ºC) and suspended in
phosphate-buffered saline (PBS) at 2 × 106 cells/mL. Briefly, to Tris-HCl buffer (pH = 7.4, 395 L/well)
were added cell suspension (50 L/well) and a test inhibitor (various concentrations, 5 L/well) or
DMSO, and the resulting suspension was pre-incubated at 37 °C for exactly 10 min. Then, Ala-MCA (1
mM in Tris-HCl buffer, 50 L/well) was added. The suspension was further incubated at 37 °C for
exactly 30 min, and AcONa-AcOH buffer (1 M, pH 4.0, 1.5 mL/well) was added. The amounts of
liberated AMC were measured in terms of fluorescence intensity (excitation at 355 nm, emission at 460
nm). The assay was performed at least in duplicate, and the mean value was taken.
ACKNOWLEDGEMENTS
The work described in this paper was partially supported by Grants-in-Aid for Scientific Research from
The Ministry of Education, Culture, Sports, Science and Technology, Japan.
REFERENCES
1. L. B. Hersh and J. F. McKelvy, J. Neurochem., 1981, 36, 171.
2. S. McLellan, S. H. Dyer, and L. B. Hersh, J. Neurochem., 1988, 51, 1552.
3. G. D. Johnson and L. B. Hersh, Arch. Biochem. Biophys., 1990, 276, 305.
4. N. D. Rawlings and A. J. Barrett, Biochem. J., 1993, 290, 201.
5. A. R. Tobler, D. B. Constam, A. Schmitt-Graff, U. Malipiero, R. Schlabach, and A. Fontana, J.

1462
HETEROCYCLES, Vol. 86, No. 2, 2012
Neurochem., 1997, 68, 889.
6. D. B. Costam, A. R. Tobler, A. Rensing-Ehl, I. Kelmer, L. B. Hersh, and A. Fontana, J. Biol. Chem.,
1995, 270, 26931.
7. M. O. Bauer, I. Nanda, G. Beck, M. Schmid, and F. Jacob, Cytogenet. Cell Genet., 2001, 92, 221.
8. L. B. Hersh and J. F. McKelvy, J. Neurochem., 1981, 36, 171.
9. L. B. Hersh, T. E. Smith, and J. F. McKelvy, Nature, 1980, 286, 160.
10. S. H. Dyer, C. A. Slaughter, K. Orth, C. R. Moomaw, and L. B. Hersh, J. Neurochem., 1990, 54, 547.
11. K. S. Hui, Neurochem. Res., 2007, 32, 2062.
12. T. Osada, S. Ikegami, K. Takiguchi-Hayashi, Y. Yamazaki, Y. Katoh-Fukui, T. Higashinakagawa, Y.
Sakaki, and T. Takeuchi, J. Neurosci., 1999, 19, 6068.
13. W. A. Peer, Ann. Bot., 2011, 107, 1171.
14. L. Stoltze, M. Schirle, G. Schwarz, C. Schroter, M. W. Thompson, L. B. Hersh, H. Kalbacher, S.
Stevanovic, H. G. Rammensee, and H. Schild, Nat. Immunol., 2000, 1, 413.
15. T. Saric, J. Beninga, C. I. Graef, T. N. Akopian, K. L. Rock, and A. L. Goldberg. J. Biol. Chem., 2001,
276, 36474.
16. C. F. Towne, I. A. York, J. Neijssen, M. L. Karow, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos,
J. J. Neefjes, and K. L. Rock, J. Immunol., 2008, 180, 1704.
17. T. Osada, Molecular Endocrinology, 2001, 15, 882.
18. T. Osada, Molecular Endocrinology, 2001, 15, 960.
19. T. Osada, S. Ikegami, K. Takiguchi-Hayashi, Y. Yamazaki, Y. Katoh-Fukui, T. Higashinakagawa, Y.
Sakaki, and T. Takeuchi, J. Neurosci., 1999, 19, 6068.
20. C. Schulz, L. Perezgasga, and M. Fuller, Dev. Genes and Evol., 2001, 211, 581.
21. S. L. Karsten, T.-K. Sang, L. T. Gehman, S. Chatterjee, J. Liu, G. M. Lawless, S. Sengupta, R. W.
Berry, J. Pomakian, H. S. Oh, C. Schulz, K.-S. Hui, M. Wiedau-Pazos, H. V. Vinters, L. I. Binder, D. H.
Geschwind, and G. R. Jackson, Neuron, 2006, 51, 549.
22. S. Sengupta, P. M. Horowitz, S. L. Karsten, G. R. Jackson, D. H. Geschwind, Y. Fu, R. W. Berry, and L.
I. Binder, Biochemistry, 2006, 45, 15111.
23. K. Yanagi, T. Tanaka, K. Kato, G. Sadik, T. Morihara, T. Kudo, and M. Takeda, Psychogeriatrics,
2009, 9, 157.
24. Y. Wang, S. Garg, E.-M. Mandelkow, and E. Mandelkow, Biochem. Soc. Trans., 2010, 38, 955.
25. L. C. Kudo, L. Parfenova, G. Ren, N. Vi, M. Hui, Z. Ma, K. Lau, M. Gray, F. Bardag-Gorce, M.
Wiedau-Pazos, K. S. Hui, and S. L. Karsten, Hum. Mol. Genet., 2011, 20, 1820.
26. K. M. Chow, H. Guan, and L. B. Hersh, Mol. Neurodegener., 2010, 5, 48.
27. N. Bhutani, P. Venkatraman, and A. L. Goldberg, EMBO J., 2007, 26, 1385.
28. F. M. Menzies, R. Hourez, S. Imarisio, M. Raspe, O. Sadiq, D. Chandraratna, C. O'Kane, K. L. Rock,

HETEROCYCLES, Vol. 86, No. 2, 2012
1463
E. Reits, A. L. Goldberg, and D. C. Rubinsztein, Hum. Mol. Genet., 2010, 19, 4573.
29. J. M. de Gandarias, J. Irazusta, J. Gil, D. Fernandez, A. Varona, and L. Casis, Brain Res. Bull., 1999,
50, 283.
30. Y. Hashimoto, Bioorg. Med. Chem., 2002, 10, 461.
31. Y. Hashimoto, Curr. Med. Chem., 1998, 5, 163.
32. R. Shimazawa, H. Takayama, Y. Fujimoto, M. Komoda, K. Dodo, Y. Yamasaki, R. Shirai, Y. Koiso, K.
Miyata, F. Kato, M. Kato, H. Miyachi, and Y. Hashimoto, J. Enzyme Inhibit., 1999, 14, 259.
33. H. Takahashi, M. Komoda, H. Kakuta, and Y. Hashimoto, Yakugaku Zasshi, 2000, 120, 909.
34. H. Kakuta, H. Takahashi, S. Sou, T. Kita, K. Nagasawa, and Y. Hashimoto, Recent Res. Develop. Med.
Chem., 2001, 1, 189.
35. H. Miyachi, M. Kato, F. Kato, and Y. Hashimoto, J. Med. Chem., 1998, 41, 263.
36. H. Kakuta, Y. Koiso, H. Takahashi, K. Nagasawa, and Y. Hashimoto, Heterocycles, 2001, 55, 1433.
37. M. Komoda, H. Kakuta, H. Takahashi, Y. Fujimoto, S. Kadoya, F. Kato, and Y. Hashimoto, Bioorg.
Med. Chem., 2001, 9, 121.
38. H. Kakuta, A. Tanatani, K. Nagasawa, and Y. Hashimoto, Chem. Pharm. Bull., 2003, 51, 1273.
39. H. Kakuta, Y. Koiso, K. Nagasawa, and Y. Hashimoto, Bioorg. Med. Chem. Lett., 2003, 13, 83.
40. J.-W. Zou, C.-C. Luo, H.-X. Zhang, H.-C. Liu, Y.-J. Jiang, and Q.-S. Yu, J. Mol. Graph. Model., 2007,
26, 494.
41. H. Kagechika, M. Komoda, Y. Fujimoto, Y. Koiso, H. Takayama, S. Kadoya, K. Miyata, F. Kato, M.
Kato, and Y. Hashimoto, Biol. Pharm. Bull., 1999, 22, 1010.
42. A. Cassidy-Stone, J. E. Chipuk, E. Ingerman, C. Song, C. Yoo, T. Kuwana, M. J. Kurth, J. T. Shaw, J.
E. Hinshaw, D. R. Green, and J. Nunnari, Dev. Cell, 2008, 14, 193.
43. A. Tanaka and R. J. Youle, Mol. Cell, 2008, 29, 409.
44. S. W. Park, K. Y. Kim, J. D. Lindsey, Y. Dai, H. Heo, D. H. Nguyen, M. H. Ellisman, R. N. Weinreb,
and W. K. Ju, Invest. Ophthalmol. Vis. Sci., 2011, 52, 2837.
45. W. Song, J. Chen, A. Petrilli, G. Liot, E. Klinglmayr, Y. Zhou, P. Poquiz, J. Tjong, M. A. Pouladi, M. R.
Hayden, E. Masliah, M. Ellisman, I. Rouiller, R. Schwarzenbacher, B. Bossy, G. Perkins, and E.
Bossy-Wetzel, Nat. Med., 2011, 17, 377.
46. A. Nakagawa, S. Uno, M. Makishima, H. Miyachi, and Y. Hashimoto, Bioorg. Med. Chem., 2008, 16,
7046.
47. I. Saiki, H. Fujii, J. Yoneda, F. Abe, M. Nakajima, T. Tsuruo, and I. Azuma, Int. J. Cancer, 1993, 54,
137.
48. G. Félix, J. Dunoguès, and R. Calas, Angew. Chem., 1979, 91, 430.